Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir With or Without Pegylated Interferon α-2b in Children With Chronic Hepatitis B
NCT07345611Phase 4Not yet recruiting
- Sponsor
- Qing-Lei Zeng
- Start
- Jan 2026
- Primary completion
- Dec 2030
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by Qing-Lei Zeng. Primary endpoint: Rate of functional cure at 120 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07345611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07345611.